Stock 2190 ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Zylox-Tonbridge Medical Technology Co., Ltd.

Equities

2190

CNE100004JD2

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:06 30/04/2024 BST 		5-day change 1st Jan Change
10.48 HKD 0.00% Intraday chart for Zylox-Tonbridge Medical Technology Co., Ltd. +3.76% -15.76%
03-22 Zylox-Tonbridge Shrinks Loss by 31% in Fiscal 2023 MT
03-21 Zylox-Tonbridge Medical Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • With an enterprise value anticipated at 4.73 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD. Stock Zylox-Tonbridge Medical Technology Co., Ltd.
-15.76% 438M -
STRYKER CORPORATION Stock Stryker Corporation
+13.16% 129B
A-
SMITH & NEPHEW PLC Stock Smith & Nephew Plc
-9.28% 10.77B
A-
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD. Stock Imeik Technology Development Co.,Ltd.
+3.60% 9.05B
C
INSPIRE MEDICAL SYSTEMS, INC. Stock Inspire Medical Systems, Inc.
+19.75% 7.38B
C
GLAUKOS CORPORATION Stock Glaukos Corporation
+22.28% 4.88B
B+
AXONICS, INC. Stock Axonics, Inc.
+7.55% 3.41B
C-
ENOVIS CORPORATION Stock Enovis Corporation
-0.21% 3.07B
B-
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD. Stock Beijing Balance Medical Technology Co.,Ltd.
-4.80% 2.24B - -
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD. Stock Shanghai MicroPort Endovascular MedTech Co., Ltd.
-4.72% 2.12B -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 2190 Stock
  4. Ratings Zylox-Tonbridge Medical Technology Co., Ltd.